Bevacizumab biosimilar is vascular endothelial growth factor directed antibody. Bevacizumab  biosimilar is a recombinant humanized monoclonal IgG1 antibody that contains human framework regions and murine complementarity-determining regions. Bevacizumab biosimilar has an approximate molecular weight of 149 kDa. Bevacizumab is produced in a mammalian cell (Chinese Hamster Ovary) expression system in a nutrient medium. 

Bevacizumab biosimilar is supplied at a concentration of 25 mg/mL as a sterile, clear to slightly opalescent, colorless to pale brown solution, which contains 60 mg/mL α,α-trehalose dihydrate, 5.8 mg/mL sodium phosphate(monobasic, monohydrate),1.2 mg/mL sodium phosphate(dibasic, anhydrous), 0.4 mg/mL polysorbate 20, and Water for Injection. 
Statement: this product is used for R&D only, not for clinical usage.

Name	Bevacizumab biosimilar
CAS NO.	216974-75-3
Type	Whole antibody
Source	Humanized (from mouse)
Target	VEGF-A
Clone	Monoclone
Formula	C6638H10160N1720O2108S44
Molecular Weight	149 kDa
Antibody Form	Purified immunoglobulin
Physical Form	Solution in phosphate buffered saline
Grade Standard	Medicine Grade
Place of Origin	China (Mainland)
Storage	-70±15℃ for long-term storage, 2-8℃ for short-term storage, away from light.

Shanghai Topwell Pharma Co., Ltd. is specialized in research, development, custom manufacturing and sales of Pharmaceutical Intermediates, APIs, Pharmaceutical Excipients, Health & Nutritional Ingredients, Polypeptides and Antibodies, etc..

Topwell has a professional R&D team. We have built close cooperative relationships with many research institutes and universities in China. In addition, we have very close cooperation relationships with many Chinese pharmaceutical factories.

Topwell aims to become a global leader in pharmaceutical & chemical industry.